Product Images Mounjaro
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 22 images provide visual information about the product associated with Mounjaro NDC 0002-1471 by Eli Lilly And Company, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Mounjaro is a medication that is administered through injection once a week. The name and dosage of the medication are legible, but no other information is available.*
This is a description not-available. The text provided is a mixture of random words, numbers, and symbols with no clear meaning or context.*
"Mounjaro (Tirzepatide) Injection" is a medication used for treatment purposes. The text also contains some numbers and code that may be related to the medication's packaging and identification.*
This text appears to be the package insert or instructions for the medication called "Mounjaro". It is administered through injection with a pen once a week. There are some unclear characters and symbols throughout the text, but the medication name and usage instructions are clear.*
The text seems to be describing a device used for medication injection. The color of the device appears to be purple and gray. There is a lock ring, a top injection button, and an indicator to show whether the device is locked or unlocked. The bottom features a clear base and a gray base cap, and there is a needle end. However, without further context, it is unclear what specific type of medication the device is designed for or any other details.*
This text appears to be a table containing information related to insulin levels and time intervals for a study or research. The first phase shows four intervals of 0, 10, 20, and 30 minutes and compares the insulin levels between Placebo-Baseline and Tirzepatide 15 mg-Baseline. The second phase shows time intervals of 60, 90, 100, 110, and 120 minutes, and compares the insulin levels between Placebo-Week 28 (with a sample size of 24) and Tirzepatide 15 mg-Week 28 (with a sample size of 41).*
This appears to be a table with values corresponding to different medications and dosages. The column header indicates "HbA1C (%)." The first column lists different medications (MOUNJARO and Semaglutide) and their varying dosages. The only value within the table is "8.0" and it's unclear what this represents. The remaining text includes "554", "T", "40", "Week 40", and "Post Randomization" but does not provide enough context to derive a useful description.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.